Amgen announces new data in ALL, R/RMM, ITP to be presented at ASH 2016
Amgen announced new data will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology, December 3-6 in San Diego. Amgen data to be presented at ASH include an oral presentation on results from a sub-analysis of the pivotal Phase 3 TOWER study evaluating the impact of BLINCYTO compared with standard of care chemotherapy on health-related quality of life in patients with relapsed or refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: Health-Related Quality of Life of Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study. Among the abstracts related to KYPROLIS is a new analysis of the pivotal Phase 3 ENDEAVOR trial that evaluates the cost-effectiveness of KYPROLIS compared to bortezomib when used in combination with dexamethasone in patients with relapsed or refractory multiple myeloma: Economic Evaluation of Carfilzomib + Dexamethasone Versus Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma. There will be an oral presentation on more than six years of data from an ongoing open-label extension study of Nplate in children with immune thrombocytopenia: A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia.